Allergan to buy Vicept for $75 million up front plus milestones
This article was originally published in Scrip
Executive Summary
Botox-maker Allergan is to acquire Vicept Therapeutics, a privately-held dermatology company, in a deal worth up to $275 million, including $75 million up front and $200 million in development milestones.